Navigation Links
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
Date:10/24/2011

HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, November 1, 2011.  Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.Conference Call Access:Date:

November 1, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

22066672To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 22066672. The audio replay will be available until November 8, 2011.  

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.  

CONTACT: Bianca Nery of An
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
3. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
6. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
7. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
10. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
11. Omega Protein Announces Retention of Lipid Technologies, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... The Perrigo Company,(Nasdaq: PRGO ; TASE) announced today ... final approval to Dexcel Pharma,Technologies, Ltd. for 20 mg ... this product for the store brand,over-the-counter (OTC) market in ... during the first quarter of calendar year 2008,with full ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer of ... tissue, today announced,financial results for the fiscal year and fourth ... Highlights for the fiscal year include:, -- Total ... of dental products increased 38% in fiscal year 2007; ...
Cached Biology Technology:ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 2Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... A UC Riverside-led research team has found that as ... they do so by increasing only that segment of ... of an individual to contribute offspring to the next ... have studied for long, the researchers found that guppies ...
... to treat diseases such as cystic fibrosis, reduce bacterial ... and the University of Texas at Austin has determined ... be pivotal in preventing certain bacterial infections in plants, ... the Proceedings of the National Academy of Sciences. ...
... the prevailing belief that adult brain cells don't grow, a ... in the Dec. 27 issue of Public Library of Science ... occur in mature brains. , This finding means that ... to replace ones damaged by disease or spinal cord injury, ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Scientists determine structure of enzyme that disrupts bacterial virulence 2MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
Sterile, individually wrapped, 4mm Cuvettes...
... fully flexible quadrupole MS detector optimized for ... 1-D and 2-D LC, as well as ... a drying gas system to create a ... for low-to-medium polarity compounds, while providing for ...
Biology Products: